Quick Answer
Shuttle Pharmaceuticals Holdings, Inc. reported Diluted EPS of $7.16 per share (loss) for fiscal year 2025.
Shuttle Pharmaceuticals Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$7.16 | +91.3% |
| 2024 | -$82.60 | -2239.9% |
| 2023 | -$3.53 | -1117.2% |
| 2022 | -$0.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.05 | +97.4% | +68.1% |
| June 30, 2025 | -$3.29 | +86.4% | -996.7% |
| March 31, 2025 | -$0.30 | +63.9% | +99.2% |
| September 30, 2024 | -$39.83 | -4276.9% | -65.1% |
| June 30, 2024 | -$24.12 | -1861.0% | -2806.0% |
| March 31, 2024 | -$0.83 | -1085.7% | +8.8% |
| September 30, 2023 | -$0.91 | -810.0% | +26.0% |
| June 30, 2023 | -$1.23 | -1950.0% | -1657.1% |
- Shuttle Pharmaceuticals Holdings, Inc. showed an increase of +91.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Shuttle Pharmaceuticals Holdings, Inc.’s diluted eps has declined by 2369.0% (from $0.29 per share (loss) to $7.16 per share (loss)).
- The most recent figure is from Shuttle Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: